William Blair analyst Andrew Brackmann has reiterated their bullish stance on BFLY stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Brackmann has given his Buy rating due to a combination of factors including Butterfly Network’s recent financial performance and future prospects. The company has surpassed consensus expectations in both revenue and adjusted EBITDA, indicating strong operational execution. Additionally, management’s optimistic outlook for 2026, particularly in overcoming the challenges of a prolonged sales cycle, adds to investor confidence.
Furthermore, the anticipated closure of hospital and enterprise deals, along with the introduction of the higher-priced P5.1 chip, supports the belief that revenue targets are attainable. The potential for growth in sectors like HomeCare and Octiv also presents significant long-term economic benefits. With shares valued at six times the projected 2026 revenue and a robust cash position, Andrew Brackmann sees Butterfly Network as having a unique and promising market offering, justifying the Buy rating.
Brackmann covers the Healthcare sector, focusing on stocks such as Exact Sciences, Hologic, and QuidelOrtho. According to TipRanks, Brackmann has an average return of 32.3% and a 68.09% success rate on recommended stocks.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $3.50 price target.